Conjunctivitis Treatment Market Trends

  • Report ID: 4553
  • Published Date: Sep 10, 2025
  • Report Format: PDF, PPT

Conjunctivitis Treatment Market Growth Drivers and Challenges:

Growth Drivers

  • Increasing Air Pollution Across the World – Exposure to indoor or outdoor air pollution can be harmful to human eyes. Tobacco smoking, cooking, and poor indoor ventilation cause eye disorders such as glaucoma, conjunctivitis, cataracts, and age-related macular degeneration. For instance, air pollution accounts for 12% of deaths in the world, and air pollution from particulate matter 2.5 leads to allergic conjunctivitis and glaucoma.

  • Rising Burden of Bacterial Conjunctivitis Infection - There are various ways that bacterial conjunctivitis can spread from person to person. These include cross-transmission from mother to child or hand-to-eye contact as well as eye contact with contaminated objects. Large respiratory tract droplets are another way through which bacteria can spread. Conjunctivitis can also result from mutations in the conventional bacteria that inhabit the conjunctiva. Thus, the surging burden of bacterial conjunctivitis infection is another factor that is estimated to fuel the growth of the global conjunctivitis treatment market in the coming years. For instance, the cost of treatment in the U.S. for only bacterial conjunctivitis is around USD 370-850 million per year.

  • Growing Globalization and Industrialization – The number of industries across the globe grew from 320 million in 2020 to 330 million in 2021, as per the estimations.

  • Rising Cases of Neonatal Conjunctivitis – In the United States, Ophthalmia neonatorum was one of the common conditions seen in nearly 1% to 12% of neonates in 2022.

  • Elevating Ratio of Sexually Transmitted Infections (STIs) – As per the World Health Organization figures, each day, over 1 million sexually transmitted infections (STIs) are acquired throughout the world, a large percentage of which show no symptoms.

Challenges

  • Associated Adverse Effects of Drugs – Many times, some medication does not suit the sensitivity of the patient and results in some more harsh outcomes such as rashes, a temporary burning or stinging sensation in an infected eye, and sometimes an issue of unstable vision after using the prescribed eye drop or ointment. Hence, this factor is anticipated to hamper the market’s growth during the projected time frame.
  • Lack of Visits to Healthcare
  • Stringent Government Regulations for Approval of New Drugs

Base Year

2025

Forecast Period

2026-2035

CAGR

4.6%

Base Year Market Size (2025)

USD 5.08 Billion

Forecast Year Market Size (2035)

USD 7.96 Billion

Regional Scope

  • North America (U.S. and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC, North Africa, South Africa, Rest of the Middle East and Africa)

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of conjunctivitis treatment is evaluated at USD 5.29 Billion.

The global conjunctivitis treatment market size was worth over USD 5.08 Billion in 2025 and is poised to grow at a CAGR of around 4.6%, reaching USD 7.96 Billion revenue by 2035.

North America conjunctivitis treatment market will hold over 36% share by 2035, driven by high corrective lens usage and healthcare infrastructure.

Key players in the market include Novartis AG, Aurobindo Pharma Limited, Cipla Limited, Viatris Inc., Akorn Operating Company LLC, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Dr.Reddy’s Laboratories Limited, MICRO LABS LIMITED, Ocular Therapeutix, Inc.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos